A method of selecting a population of adherent cells of a placenta tissue suitable for treating ischemia, wherein said adherent cells are ex-vivo expanded, the method comprising: (a) determining prior to transplantation in a candidate population of adherent cells of a placenta tissue the following parameters: (i) percentage of viable cells in said candidate population; (ii) immune phenotype of cells in said candidate population; (iii) xeno-contamination in said candidate population; (iv) sterility of said candidate population; and (v) immunosuppressive activity of cells in said candidate population; (b) selecting said candidate population according to the following values: (i) at least 70% of viable cells in said candidate population; and (ii) said immune phenotype comprising a positive marker expression of CD73, CD29 and CD105 and a negative marker expression of CD45, CD14 and HLA-DR of cells in said candidate population, wherein cells comprising said positive marker expression make up at least 90% of said candidate population and cells comprising said negative marker expression make up equally to or less than 3% of said candidate population; (iii) no xeno-contamination in said candidate population; (iv) sterility of said candidate population; and (v) immunosuppressive activity of cells in said candidate population, as determined using a Mixed Lymphocyte Reaction or a Phytohemagglutinin assay, thereby selecting a population of adherent cells of said placenta tissue suitable for treating ischemia. (a) determining prior to transplantation in a candidate population of adherent cells of a placenta tissue the following parameters: (i) percentage of viable cells in said candidate population; (ii) immune phenotype of cells in said candidate population; (iii) xeno-contamination in said candidate population; (iv) sterility of said candidate population; and (v) immunosuppressive activity of cells in said candidate population; (i) percentage of viable cells in said candidate population; (ii) immune phenotype of cells in said candidate population; (iii) xeno-contamination in said candidate population; (iv) sterility of said candidate population; and (v) immunosuppressive activity of cells in said candidate population; (b) selecting said candidate population according to the following values: (i) at least 70% of viable cells in said candidate population; and (ii) said immune phenotype comprising a positive marker expression of CD73, CD29 and CD105 and a negative marker expression of CD45, CD14 and HLA-DR of cells in said candidate population, wherein cells comprising said positive marker expression make up at least 90% of said candidate population and cells comprising said negative marker expression make up equally to or less than 3% of said candidate population; (iii) no xeno-contamination in said candidate population; (iv) sterility of said candidate population; and (v) immunosuppressive activity of cells in said candidate population, as determined using a Mixed Lymphocyte Reaction or a Phytohemagglutinin assay, (i) at least 70% of viable cells in said candidate population; and (ii) said immune phenotype comprising a positive marker expression of CD73, CD29 and CD105 and a negative marker expression of CD45, CD14 and HLA-DR of cells in said candidate population, wherein cells comprising said positive marker expression make up at least 90% of said candidate population and cells comprising said negative marker expression make up equally to or less than 3% of said candidate population; (iii) no xeno-contamination in said candidate population; (iv) sterility of said candidate population; and (v) immunosuppressive activity of cells in said candidate population, as determined using a Mixed Lymphocyte Reaction or a Phytohemagglutinin assay,